Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera (Nasdaq: BFRI) announced its participation in The Benchmark Healthcare House Call Virtual 1x1 Conference on June 2, 2022. Erica Monaco, CEO, and Hermann Lübbert, Executive Chairman, will engage with registered investors through virtual meetings and small group sessions.
Biofrontera is a biopharmaceutical company focused on dermatological products, including treatments for actinic keratoses and impetigo. For further information, visit biofrontera-us.com.
- None.
- None.
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1 Conference being held on June 2, 2022.
Erica Monaco, Chief Executive Officer and Hermann Lübbert, Executive Chairman of Biofrontera Inc. will be meeting with registered investors in virtual one-on-one meetings and small-group sessions.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com.
Contacts
Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com
# # #
FAQ
When is Biofrontera's participation in The Benchmark Healthcare House Call Conference?
Who will represent Biofrontera at the conference?
What is the focus of Biofrontera's products?
What is the stock symbol for Biofrontera?
Where can I find more information about Biofrontera?
